Drug Profile
Trastuzumab biosimilar - BioXpress Therapeutics
Alternative Names: BX-2318; BXT-2318Latest Information Update: 05 Dec 2022
Price :
$50
*
At a glance
- Originator BioXpress Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Breast cancer
Highest Development Phases
- Clinical Phase Unknown HER2 positive breast cancer
Most Recent Events
- 05 Dec 2022 Trastuzumab biosimilar is still in clinical trials for HER2-positive-breast-cancer in Switzerland (BioXpress Therapeutics pipeline, December 2022)
- 28 Aug 2021 No recent reports of development identified for clinical-Phase-Unknown development in HER2-positive-breast-cancer in Switzerland (IV, Infusion)
- 29 Aug 2019 Trastuzumab biosimilar is still in clinical-Phase in HER2-positive-breast-cancer in Switzerland (IV, Infusion)